Invega Sustenna Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Alerts
• Clinical Trials
• Forums

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Condition:   SchizophreniaIntervention:   Drug: Paliperidone palmitate 3 month formulation (PP3M)Sponsor:   Janssen-Cilag International NVNot yet recruiting - verified March 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2016 Category: Research Source Type: clinical trials